The Worldwide Market for High Content Screening (HCS) 2019 to 2024 - The Market is Projected to Cross $1 Billion by 2024 -

DUBLIN--()--The "High Content Screening Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

The high content screening market was valued at around USD 600 million and is expected to reach a market value of approximately USD 1.05 billion, by registering a growth rate of 9.8%.

Under the conventional method of toxicity studies, large libraries are screened in search of potential drug candidates. This method is expensive, resource- and time-consuming, and has a low success rate. Consequently, high content screening (HCS) solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in-vitro toxicity testing by reducing the time and cost.

The need for cost containment in pharmaceutical R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine, present significant growth opportunities in the market.

Key Market Trends

On the basis of Product Type, Instrument segment led the global market in 2018

Based on the product segment, the high content screening market is further segmented into instruments, consumables, software, services, and accessories. The market for HCS software is expected to increase with the highest CAGR between 2019 and 2024. Among all high content screening products, the instrument segment occupies the largest share of the market. The large share of this segment is attributed to advances in instrumentation and automation techniques and high prices of HCS instruments.

APAC region is expected to exhibit the highest growth rate

The high content screening market in APAC is expected to increase at the highest CAGR during the forecast period. Factors, such as increasing drug discovery research, government initiatives, growing focus of multinational companies on emerging markets, and developing R&D infrastructure are driving the growth of the HCS market in this region.

Competitive Landscape

For compound profiling applications, many pharmaceutical companies are partnering with contract research organizations to identify potential candidates for drug discovery. The HCS market is highly competitive in nature. The majority of large global players are based out of the United States and these players have expertise in other biotechnology/medical-technology verticals as well, which helps them in controlling the major market share, through a presence in the allied markets.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Need for Cost Containment in Pharmaceutical R&D

4.2.2 Government Funding and Venture Capital Investments Across Developed Markets

4.2.3 Advancements in Informatics Solutions and Imaging Instruments

4.3 Market Restraints

4.3.1 Lower Adoption of HCS Instruments Due to Their High Prices

4.4 Porter's Five Forces Analysis


5.1 Product

5.1.1 Instruments Cell Imaging and Analysis Systems Flow Cytometers

5.1.2 Consumables Reagents and Assay Kits Microplates Other Consumables

5.1.3 Software

5.1.4 Services

5.1.5 Accessories

5.2 Application

5.2.1 Primary and Secondary Screening

5.2.2 Target Identification and Validation

5.2.3 Toxicity Studies

5.2.4 Compound Profiling

5.2.5 Other Applications

5.3 End User

5.3.1 Pharmaceutical and Biotechnology Companies

5.3.2 Academic and Government Institutions

5.3.3 Contract Research Organisation

5.4 Geography

5.4.1 North America

5.4.2 Europe

5.4.3 Asia-Pacific

5.4.4 Middle East & Africa

5.4.5 South America


6.1 Company Profiles

6.1.1 GE Healthcare

6.1.2 Danaher Corporation

6.1.3 Perkinelmer Inc.

6.1.4 Thermo Fisher Scientific Inc.

6.1.5 Becton, Dickinson and Company

6.1.6 Biotek Instruments Inc.

6.1.7 Bio-Rad Laboratories Inc.

6.1.8 Yokogawa Electric Corporation

6.1.9 Merck Millipore


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery